Abstract: Disclosed herein are engineered oligonucleotides for selective inhibition of polypeptide expression and activity. Also disclosed herein are methods of selectively inhibiting polypeptide expression and activity contacting an engineered oligonucleotide with a polynucleotide encoding the polypeptide.
Type:
Grant
Filed:
March 11, 2022
Date of Patent:
October 24, 2023
Assignee:
MIRECULE, INC.
Inventors:
Robert Place, Anthony Saleh, Tishan Williams
Abstract: Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5?-end and/or 3?-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.
Type:
Application
Filed:
April 14, 2023
Publication date:
September 21, 2023
Applicants:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services, miRecule, Inc.
Inventors:
Anthony D. Saleh, Carter Van Waes, Zhong Chen, Hui Cheng
Abstract: Disclosed herein are engineered oligonucleotides for selective inhibition of polypeptide expression and activity. Also disclosed herein are methods of selectively inhibiting polypeptide expression and activity contacting an engineered oligonucleotide with a polynucleotide encoding the polypeptide.
Type:
Grant
Filed:
March 11, 2022
Date of Patent:
March 7, 2023
Assignee:
MIRECULE, INC.
Inventors:
Robert Place, Anthony Saleh, Tishan Williams
Abstract: Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5?-end and/or 3?-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.
Type:
Application
Filed:
March 7, 2017
Publication date:
September 19, 2019
Applicants:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services, miRecule, Inc.
Inventors:
Anthony D. Saleh, Carter Van Waes, Zhong Chen, Hui Cheng